Loading...
Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients?
After 4 years of early benefit assessment (EBA) in Germany, it is becoming evident that the Federal Joint Committee (FJC) frequently considers well-established clinical endpoints as not being relevant to patients. Focusing on assessments of oncology medicines, we analysed the FJC’s view on primary e...
Saved in:
| Published in: | Drugs R D |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Springer International Publishing
2015
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4561053/ https://ncbi.nlm.nih.gov/pubmed/26286202 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40268-015-0100-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|